Clinicians Treating Refractory Relapse ALL Should Consider Using Inotuzumab

Cancer-News has 181 videos Subscribe Here

Description: Hagop M. Kantarjian, MD of MD Anderson Cancer Center's Department of Leukemia says now that Besponsa or Inotuzumab is FDA approved that clinicians clinicians treating refractory relapse ALL should consider Inotuzumab for their patients.
Shared By : Cancer-News
Posted on : 08/31/17
Added : 2 years ago